Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer

Season 3 Episode 40  ·  Sep 21, 2020, 09:34 PM
Headliner
Share
Subscribe

In our exclusive interview, Dr. Tripathy, discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

Share
Subscribe
Next
FDA Approval Insights: Lurbinectedin in Metastatic SCLC
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air